06.25.26 -- Better Biopharma's Editors' Roundtable — A Midyear Look At The 2026 Life Sciences Industry

Gene therapy immunogenicity requires platforms, judgment, and regulatory fluency beyond ADA norms. Relying on biologics criteria creates gaps; CGT expertise ensures reliable, interpretable results.

An expert-led webinar exploring nucleic acid therapeutic modalities, delivery systems, formulation challenges, and real-world case studies shaping drug product development.

Economic volatility, regulatory uncertainty, and capacity constraints pose major risks to CDMOs, threatening growth, profitability, and long-term sustainability in an increasingly competitive global market.

Europe’s integrated CDMO model is reshaping biologics development by aligning early science, manufacturing, and quality to accelerate scalable, compliant therapies from concept to clinic.

Assimilate how advanced therapy supply chains are evolving toward patient-centric, risk-managed, digitally connected models to support scale, reliability, and regulatory confidence globally today.

Discover how the Alerion™ Microbubble Cell Separation System outperformed standard magnetic methods in T cell recovery, speed, and scalability — achieving higher cell quality with Akadeum’s innovative microbubble technology.

Comparing plasmid DNA to enzymatically produced DNA shows how enzymatic methods cut manufacturing costs, speed production, and boost efficiency for large‑scale AAV gene therapy.